Mezzanine Management sells Optimapharm to Rohatyn Group
Mezzanine Management has sold Croatian contract research organisation Optimapharm to asset management firm The Rohatyn Group (TRG).
More on CEE
TriSpan Opportunities Fund II holds first close
Fund focuses on investment opportunities in the lower-mid-market across North America and Europe
Kartesia in €32m refinancing for Enterprise-backed Nu-Med
Enterprise Investors acquired a minority stake in the oncology company in 2013
Abris Capital buys Scanmed for PLN 340m
GP invests in the company via Abris CEE Mid-Market III, which held a final close on its €500m target in 2017
SR One set to deploy $500m fund following GSK spin-out
CEO Simeon George tells Unquote that the firm is seeing early-stage and later-stage opportunities
Latest News
Deutsche Beteiligungs AG announces supervisory board changes
Tom Alzin and Jannick Hunnecke will join, while Rolf Scheffels is to leave when his term ends
TriSpan Opportunities Fund II holds first close
Fund focuses on investment opportunities in the lower-mid-market across North America and Europe
Duff & Phelps appoints Bretag
Frank Bretag joins from Georgieff Capital Advisors and focuses on the industrial goods sector
Kartesia in €32m refinancing for Enterprise-backed Nu-Med
Enterprise Investors acquired a minority stake in the oncology company in 2013